Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

Single Arm Phase II Study of Bladder Preservation With Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (BRIGHT)

NCT ID: NCT07061964Sponsor: National Cancer Institute (NCI)Last updated: 2026-06-11

Summary

This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy includes chemotherapy before surgery (neoadjuvant) to shrink or get rid of the tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Photon beam radiation therapy is a type of radiation therapy that uses x-rays or gamma rays that come from a special machine called a linear accelerator. The radiation dose is delivered at the surface of the body and goes into the tumor and through the body. Giving pembrolizumab in combination with radiation therapy after neoadjuvant chemotherapy may help prevent surgical removal of the bladder in patients with muscle invasive bladder cancer.

Detailed description

PRIMARY OBJECTIVE: I. To evaluate whether 3-year bladder intact event-free survival (BI-EFS) is at least 70% in participants with clinically T0-clinically T1 without multifocal carcinoma in situ (CIS) following neoadjuvant therapy (NAT) for muscle-invasive bladder cancer (MIBC) who receive radiotherapy (RT) + pembrolizumab (MK-3475). SECONDARY OBJECTIVES: I. To estimate BI-EFS in participants who receive RT + pembrolizumab (MK-3475). II. To estimate local muscle invasive recurrence-free survival in participants who receive RT+ pembrolizumab (MK-3475). III. To estimate the metastasis-free survival (MFS) in participants who receive RT+ pembrolizumab (MK-3475). IV. To estimate the overall survival (OS) in participants who receive RT + pembrolizumab (MK-3475). V. To estimate the rate of salvage cystectomy in participants who receive RT+ pembrolizumab (MK-3475). VI. To evaluate the frequency and severity of toxicities in participants who receive RT + pembrolizumab (MK-3475). PATIENT REPORTED OUTCOMES (PRO)-COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE) OBJECTIVE: I. To evaluate participant-reported symptoms using selected items from Gastrointestinal, Genitourinary and sexual function domains of the PRO-CTCAE, with the goal of characterizing the frequency, severity, and interference of treatment-related symptoms. BANKING OBJECTIVE: I. To bank specimens for future correlative studies. OUTLINE: Patients undergo photon beam RT once daily (QD) on Monday-Friday for up to 20 treatments and receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 18 cycles (for a total of 12 months, including NAT) in the absence of disease progression or unacceptable toxicity. Patients also undergo transurethral resection of bladder tumor (TURBT) with tissue sample collection at pre-registration and computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography (PET), cystoscopy, and urine and blood sample collection throughout the study. After completion of study treatment, patients are followed every 26 weeks until year 2 and then every 52 weeks up to year 5.

Arms & interventions

  • ProcedureBiospecimen Collection

    Undergo tissue, urine, and blood sample collection

  • ProcedureComputed Tomography

    Undergo CT

  • ProcedureCystoscopy

    Undergo cystoscopy

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

  • BiologicalPembrolizumab

    Given IV

  • RadiationPhoton Beam Radiation Therapy

    Undergo photon beam RT

  • ProcedurePositron Emission Tomography

    Undergo PET

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureTransurethral Resection of Bladder Tumor

    Undergo TURBT

Outcome measures

Primary

  • Bladder intact event-free survival (BI-EFS)

    Will be evaluated as the percentage of participants who do not experience a BI-EFS event using a Kaplan-Meier estimate. A single-arm test of proportions will be used to test against the null hypothesis (true BI-EFS = 55%). Standard errors will be calculated using Greenwood's formula. If the upper bound of the one-sided 90% confidence interval includes 70%, then the radiation therapy + pembrolizumab regimen will be concluded to be active in this population.

    Time frame: Within 3 years after registration

Secondary

  • BI-EFS

    Time frame: From registration to the first documentation of a BI-EFS event, assessed up to 5 years

  • Local muscle invasive recurrence-free survival

    Time frame: From date of registration to first radiologic or histologic evidence of local muscle invasive bladder carcinoma recurrence, assessed up to 5 years

  • Metastasis-free survival

    Time frame: From date of registration to first radiologic or histologic evidence of metastatic disease or death due to any cause, assessed up to 5 years

  • Overall survival

    Time frame: From date of registration to date of death due to any cause, assessed up to 5 years

  • Salvage cystectomy

    Time frame: Up to 5 years

  • Incidence of adverse events

    Time frame: Up to 30 days after last dose of study treatment

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Participants must have histologic evidence of cT2-T4aN0M0 muscle invasive urothelial carcinoma of the bladder within 180 days prior to starting neoadjuvant therapy (NAT) * Participants must have had CT chest/abdomen/pelvis (C/A/P), MRI C/A/P or PET within 60 days prior to starting NAT to determine cT2-T4aN0M0 * Participants must have undergone TURBT with biopsy of areas of prior disease and systematic biopsies (left and right lateral, dome, posterior wall and trigone) and radiologic staging showing clinically T0-T1 disease within 60 days after the last dose of NAT. At least 4 out of 5 systematic biopsies must be performed * NOTE: This TURBT must be within 90 days prior to registration. Registration must be within 90 days after the last dose of NAT * Participants must have imaging of the chest, abdomen, and pelvis performed using CT or MRI preferably with contrast. Fludeoxyglucose F-18 (FDG) PET-CT can also be used for staging. If FDG PET-CT is used, then it is at the discretion of the investigator if they want to additionally obtain diagnostic CT or MRI with contrast within 60 days after the last dose of NAT * Participants with lymph nodes ≥ 1.0 cm in the shortest cross-sectional diameter on imaging (CT or MRI of abdomen and pelvis) after completion of NAT must have a PET-CT within 70 days prior to registration. A biopsy in the setting of negative PET-CT is not required unless there is strong clinical suspicion for nodal involvement with tumor. Participants with a positive PET are deemed ineligible unless a biopsy is performed and shows no evidence of tumor involvement * NOTE: For questions regarding the above eligibility criteria, please contact the study chairs in addition to the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC) * Participants must not have evidence of ≥ T2, or N1-3, or M1 disease after NAT * Participants must not have the presence of small cell, neuroendocrine carcinoma, plasmacytoid variants on any pathology * Participants must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder within 24 months prior to registration except Ta/T1/carcinoma in situ (CIS) of the upper urinary tract, including renal pelvis or ureter if the participant underwent complete nephroureterectomy * NOTE: Participants with mixed variant histology will be eligible for the trial if the majority (\> 50%) of the tumor is urothelial cell carcinoma * Participants will be allowed to continue PD-1/L-1 inhibitor therapy received as part of standard of care neoadjuvant therapy while they undergo pre-registration assessments (TURBT and imaging) * Participants must have received at least 3 and no more than 6 cycles of Food and Drug Administration (FDA) approved NAT for MIBC. These include cisplatin-based combination chemotherapy (e.g. cisplatin and gemcitabine \[GC\] with or without PD-1/L1 inhibitors) dose dense or accelerated methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) or enfortumab vedotin with PD-1/L1 inhibitor * Participants must not have had anti-PD-1, anti PD-L1, anti PD-L2 or anti-CTLA4 antibody, any other antibody or drug targeting T-cell co-stimulation, enfortumab vedotin, or any other drug targeting nectin-4 other than for neoadjuvant treatment for MIBC * NOTE: Prior intravesical immunotherapy or chemotherapy for non-muscle invasive disease is allowed * Participants must not have had prior pelvic radiotherapy * Participants must not have received a live attenuated vaccination within 28 days prior to registration * Participants with conditions requiring immunosuppressive doses of steroids (\> 10 mg/day of prednisone or equivalent) or other immunosuppressive medications must not be taking steroids at time of trial registration * Participants must be ≥ 18 years old at the time of registration * Participants must have Zubrod performance status of 0-2 * Participants must have a complete medical history and physical exam within 28 days prior to registration * Leukocytes ≥ 3 x 10\^3/uL (within 28 days prior to registration) * Absolute neutrophil count ≥ 1.5 x 10\^3/uL (within 28 days prior to registration) * Platelets ≥ 100 x 10\^3/uL (within 28 days prior to registration) * Total bilirubin ≤ institutional upper limit of normal (ULN) unless history of Gilbert's disease (within 28 days prior to registration) * Participants with history of Gilbert's disease must have total bilirubin ≤ 5 x institutional ULN * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 x institutional ULN (within 28 days prior to registration) * Participants must have a creatinine ≤ the institutional (I)ULN OR measured OR calculated creatinine clearance ≥ 40 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration * Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better * Participants with a history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration * For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured (defined as undetectable HCV viral load) * Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen * Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen * Participants must be offered the opportunity to participate in specimen banking * Participants who can complete the PRO-CTCAE questionnaire in English or Spanish will be offered the opportunity to participate in the optional patient-reported outcome study * NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines * For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and central institutional review board (CIRB) regulations

Study locations (143)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233

Recruiting
Site Public Contact · Contact
gingerreeves@uabmc.edu
Charles C. Peyton · Principal Investigator

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234

Recruiting
Site Public Contact · Contact
602-747-9738
Chinedu Mmeje · Principal Investigator

Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054

Recruiting
Site Public Contact · Contact
855-776-0015
Mark D. Tyson · Principal Investigator

Highlands Oncology Group - Fayetteville

Fayetteville, Arkansas, 72703

Recruiting
Site Public Contact · Contact
479-872-8100research@hogonc.com
Joseph T. Beck · Principal Investigator

Highlands Oncology Group - Rogers

Rogers, Arkansas, 72758

Recruiting
Site Public Contact · Contact
479-872-8130research@hogonc.com
Joseph T. Beck · Principal Investigator

Highlands Oncology Group

Springdale, Arkansas, 72762

Recruiting
Site Public Contact · Contact
479-872-8130research@hogonc.com
Joseph T. Beck · Principal Investigator

Tower Cancer Research Foundation

Beverly Hills, California, 90211

Recruiting
Site Public Contact · Contact
towercancerresearch@toweroncology.com
Leslie Ballas · Principal Investigator

City of Hope Corona

Corona, California, 92882

Recruiting
Site Public Contact · Contact
626-256-4673becomingapatient@coh.org
Abhishek Tripathi · Principal Investigator

City of Hope Comprehensive Cancer Center

Duarte, California, 91010

Recruiting
Site Public Contact · Contact
800-826-4673becomingapatient@coh.org
Abhishek Tripathi · Principal Investigator

City of Hope at Irvine Lennar

Irvine, California, 92618

Recruiting
Site Public Contact · Contact
877-467-3411
Abhishek Tripathi · Principal Investigator

City of Hope Antelope Valley

Lancaster, California, 93534

Recruiting
Site Public Contact · Contact
800-826-4673becomingapatient@coh.org
Abhishek Tripathi · Principal Investigator

Los Angeles General Medical Center

Los Angeles, California, 90033

Recruiting
Site Public Contact · Contact
323-865-0451uscnorrisinfo@med.usc.edu
Siamak Daneshmand · Principal Investigator

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033

Recruiting
Site Public Contact · Contact
323-865-0451
Siamak Daneshmand · Principal Investigator

Cedars-Sinai Medical Center

Los Angeles, California, 90048

Recruiting
Site Public Contact · Contact
310-423-2133Cancer.trial.info@cshs.org
Leslie Ballas · Principal Investigator

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817

Recruiting
Site Public Contact · Contact
916-734-3089
Mamta Parikh · Principal Investigator

City of Hope South Pasadena

South Pasadena, California, 91030

Recruiting
Site Public Contact · Contact
800-826-4673becomingapatient@coh.org
Abhishek Tripathi · Principal Investigator

Cedars-Sinai Cancer - Tarzana

Tarzana, California, 91356

Recruiting
Site Public Contact · Contact
818-981-3818
Leslie Ballas · Principal Investigator

City of Hope Upland

Upland, California, 91786

Recruiting
Site Public Contact · Contact
800-826-4673becomingapatient@coh.org
Abhishek Tripathi · Principal Investigator

UCHealth University of Colorado Hospital

Aurora, Colorado, 80045

Recruiting
Site Public Contact · Contact
720-848-0650
Tyler Robin · Principal Investigator

UCHealth - Cherry Creek

Denver, Colorado, 80206

Recruiting
Site Public Contact · Contact
protocols@swog.org
Tyler Robin · Principal Investigator

Shaw Cancer Center

Edwards, Colorado, 81632

Recruiting
Site Public Contact · Contact
970-569-7429
Erin Schwab · Principal Investigator

Poudre Valley Hospital

Fort Collins, Colorado, 80524

Recruiting
Site Public Contact · Contact
970-297-6150
Tyler Robin · Principal Investigator

Cancer Care and Hematology-Fort Collins

Fort Collins, Colorado, 80528

Recruiting
Site Public Contact · Contact
protocols@swog.org
Tyler Robin · Principal Investigator

UCHealth Greeley Hospital

Greeley, Colorado, 80631

Recruiting
Site Public Contact · Contact
protocols@swog.org
Tyler Robin · Principal Investigator

UCHealth Highlands Ranch Hospital

Highlands Ranch, Colorado, 80129

Recruiting
Site Public Contact · Contact
720-848-0650
Tyler Robin · Principal Investigator

UCHealth Lone Tree Health Center

Lone Tree, Colorado, 80124

Recruiting
Site Public Contact · Contact
protocols@swog.org
Tyler Robin · Principal Investigator

Medical Center of the Rockies

Loveland, Colorado, 80538

Recruiting
Site Public Contact · Contact
970-203-7083
Tyler Robin · Principal Investigator

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980

Recruiting
Site Public Contact · Contact
855-776-0015
Mark D. Tyson · Principal Investigator

Moffitt Cancer Center at SouthShore

Ruskin, Florida, 33570

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
George D. Grass · Principal Investigator

Moffitt Cancer Center-International Plaza

Tampa, Florida, 33607

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
George D. Grass · Principal Investigator

Moffitt Cancer Center - McKinley Campus

Tampa, Florida, 33612

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
George D. Grass · Principal Investigator

Moffitt Cancer Center

Tampa, Florida, 33612

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
George D. Grass · Principal Investigator

Moffitt Cancer Center at Wesley Chapel

Wesley Chapel, Florida, 33544

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
George D. Grass · Principal Investigator

CTCA at Southeastern Regional Medical Center

Newnan, Georgia, 30265

Recruiting
Site Public Contact · Contact
770-400-6629
Bamidele A. Adesunloye · Principal Investigator

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

Suspended

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

Suspended

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864

Suspended

Rush-Copley Medical Center

Aurora, Illinois, 60504

Recruiting
Site Public Contact · Contact
630-978-6212RCMC_Cancer_Research@rush.edu
Priyank P. Patel · Principal Investigator

OSF Saint Joseph Medical Center

Bloomington, Illinois, 61701

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Bloomington

Bloomington, Illinois, 61704

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Canton

Canton, Illinois, 61520

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Carthage

Carthage, Illinois, 62321

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Northwestern University

Chicago, Illinois, 60611

Recruiting
Site Public Contact · Contact
312-695-1301cancer@northwestern.edu
Sean Sachdev · Principal Investigator

Carle at The Riverfront

Danville, Illinois, 61832

Recruiting
Site Public Contact · Contact
800-446-5532Research@Carle.com
Priyank P. Patel · Principal Investigator

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Decatur Memorial Hospital

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Northwestern Medicine Cancer Center Kishwaukee

DeKalb, Illinois, 60115

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Sean Sachdev · Principal Investigator

Illinois CancerCare-Dixon

Dixon, Illinois, 61021

Suspended

Carle Physician Group-Effingham

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Priyank P. Patel · Principal Investigator

Crossroads Cancer Center

Effingham, Illinois, 62401

Suspended

Illinois CancerCare-Eureka

Eureka, Illinois, 61530

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201

Recruiting
Site Public Contact · Contact
847-570-2109
Nicklas R. Pfanzelter · Principal Investigator

Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Northwestern Medicine Cancer Center Delnor

Geneva, Illinois, 60134

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Sean Sachdev · Principal Investigator

NorthShore University HealthSystem-Glenbrook Hospital

Glenview, Illinois, 60026

Recruiting
Site Public Contact · Contact
847-570-2109
Nicklas R. Pfanzelter · Principal Investigator

Northwestern Medicine Glenview Outpatient Center

Glenview, Illinois, 60026

Recruiting
Site Public Contact · Contact
312-695-1102
Sean Sachdev · Principal Investigator

Northwestern Medicine Grayslake Outpatient Center

Grayslake, Illinois, 60030

Recruiting
Site Public Contact · Contact
312-695-1102
Sean Sachdev · Principal Investigator

NorthShore University HealthSystem-Highland Park Hospital

Highland Park, Illinois, 60035

Recruiting
Site Public Contact · Contact
847-570-2109
Nicklas R. Pfanzelter · Principal Investigator

Illinois CancerCare-Kewanee Clinic

Kewanee, Illinois, 61443

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Northwestern Medicine Lake Forest Hospital

Lake Forest, Illinois, 60045

Recruiting
Site Public Contact · Contact
cancertrials@northwestern.edu
Sean Sachdev · Principal Investigator

Illinois CancerCare-Macomb

Macomb, Illinois, 61455

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Priyank P. Patel · Principal Investigator

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

HSHS Saint Elizabeth's Hospital

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Northwestern Medicine Oak Brook

Oak Brook, Illinois, 60523

Recruiting
Site Public Contact · Contact
nctnprogram_rhlccc@northwestern.edu
Sean Sachdev · Principal Investigator

Northwestern Medicine Orland Park

Orland Park, Illinois, 60462

Recruiting
Site Public Contact · Contact
nctnprogram_rhlccc@northwestern.edu
Sean Sachdev · Principal Investigator

Illinois CancerCare-Ottawa Clinic

Ottawa, Illinois, 61350

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Pekin

Pekin, Illinois, 61554

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Peoria

Peoria, Illinois, 61615

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

OSF Saint Francis Radiation Oncology at Peoria Cancer Center

Peoria, Illinois, 61615

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

OSF Saint Francis Medical Center

Peoria, Illinois, 61637

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Peru

Peru, Illinois, 61354

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Princeton

Princeton, Illinois, 61356

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
217-545-7929
Bryan A. Faller · Principal Investigator

Springfield Clinic

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
800-444-7541
Bryan A. Faller · Principal Investigator

Springfield Memorial Hospital

Springfield, Illinois, 62781

Recruiting
Site Public Contact · Contact
217-528-7541pallante.beth@mhsil.com
Bryan A. Faller · Principal Investigator

Carle Cancer Center

Urbana, Illinois, 61801

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Priyank P. Patel · Principal Investigator

Northwestern Medicine Cancer Center Warrenville

Warrenville, Illinois, 60555

Recruiting
Site Public Contact · Contact
630-352-5360Donald.Smith3@nm.org
Sean Sachdev · Principal Investigator

Illinois CancerCare - Washington

Washington, Illinois, 61571

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Mary Greeley Medical Center

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Ames

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-239-4734ksoder@mcfarlandclinic.com
Joseph J. Merchant · Principal Investigator

UI Health Care Mission Cancer and Blood - Ankeny Clinic

Ankeny, Iowa, 50023

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

McFarland Clinic - Boone

Boone, Iowa, 50036

Suspended

Mercy Cancer Center-West Lakes

Clive, Iowa, 50325

Recruiting
Site Public Contact · Contact
515-241-3305
Richard L. Deming · Principal Investigator

UI Health Care Mission Cancer and Blood - West Des Moines Clinic

Clive, Iowa, 50325

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Iowa Methodist Medical Center

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-241-6727
Seema Harichand-Herdt · Principal Investigator

UI Health Care Mission Cancer and Blood - Des Moines Clinic

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-241-3305
Richard L. Deming · Principal Investigator

UI Health Care Mission Cancer and Blood - Laurel Clinic

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

McFarland Clinic - Trinity Cancer Center

Fort Dodge, Iowa, 50501

Suspended

McFarland Clinic - Jefferson

Jefferson, Iowa, 50129

Suspended

McFarland Clinic - Marshalltown

Marshalltown, Iowa, 50158

Suspended

UI Health Care Mission Cancer and Blood - Waukee Clinic

Waukee, Iowa, 50263

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

The Iowa Clinic PC

West Des Moines, Iowa, 50266

Recruiting
Site Public Contact · Contact
515-875-9815
Seema Harichand-Herdt · Principal Investigator

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

Recruiting
Site Public Contact · Contact
859-257-3379
Insija Ilyas Selene · Principal Investigator

The James Graham Brown Cancer Center at University of Louisville

Louisville, Kentucky, 40202

Recruiting
Site Public Contact · Contact
502-562-3429
Scott R. Silva · Principal Investigator

UofL Health Medical Center Northeast

Louisville, Kentucky, 40245

Recruiting
Site Public Contact · Contact
502-852-2755ctoinfo@louisville.edu
Scott R. Silva · Principal Investigator

University Medical Center New Orleans

New Orleans, Louisiana, 70112

Recruiting
Site Public Contact · Contact
504-210-3539emede1@lsuhsc.edu
Rajasree P. Chowdry · Principal Investigator

Tufts Medical Center

Boston, Massachusetts, 02111

Recruiting
Site Public Contact · Contact
617-636-5000ContactUsCancerCenter@TuftsMedicalCenter.org
Brett Diamond · Principal Investigator

UMass Memorial Medical Center - University Campus

Worcester, Massachusetts, 01655

Recruiting
Site Public Contact · Contact
508-856-3216cancer.research@umassmed.edu
Kriti Mittal · Principal Investigator

Sanford Joe Lueken Cancer Center

Bemidji, Minnesota, 56601

Recruiting
Site Public Contact · Contact
218-333-5000OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Fairview Southdale Hospital

Edina, Minnesota, 55435

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
David M. King · Principal Investigator

University of Mississippi Medical Center

Jackson, Mississippi, 39216

Recruiting
Site Public Contact · Contact
601-815-6700
John C. Henegan · Principal Investigator

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703

Recruiting
Site Public Contact · Contact
573-334-2230sfmc@sfmc.net
Bryan A. Faller · Principal Investigator

Billings Clinic Cancer Center

Billings, Montana, 59101

Recruiting
Site Public Contact · Contact
800-996-2663research@billingsclinic.org
John M. Schallenkamp · Principal Investigator

Community Medical Center

Missoula, Montana, 59804

Suspended

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon, New Hampshire, 03756

Recruiting
Site Public Contact · Contact
800-639-6918cancer.research.nurse@dartmouth.edu
James B. Yu · Principal Investigator

Hunterdon Medical Center

Flemington, New Jersey, 08822

Recruiting
Site Public Contact · Contact
908-237-2330
Myron E. Bednar · Principal Investigator

Jersey City Medical Center

Jersey City, New Jersey, 07302

Recruiting
Site Public Contact · Contact
888-823-5923ctsucontact@westat.com
Lara Hathout · Principal Investigator

Saint Barnabas Medical Center

Livingston, New Jersey, 07039

Recruiting
Site Public Contact · Contact
973-322-2934joanne.loeb@rwjbh.org
Lara Hathout · Principal Investigator

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903

Recruiting
Site Public Contact · Contact
732-235-7356
Lara Hathout · Principal Investigator

The New York Hospital Medical Center of Queens

Flushing, New York, 11355

Recruiting
Site Public Contact · Contact
888-823-5923ctsucontact@westat.com
Leen Khoury · Principal Investigator

NYP/Weill Cornell Medical Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-746-1848
Rohit Jain · Principal Investigator

Stony Brook University Medical Center

Stony Brook, New York, 11794

Recruiting
Site Public Contact · Contact
800-862-2215
Judy Huang · Principal Investigator

Sanford Broadway Medical Center

Fargo, North Dakota, 58122

Recruiting
Site Public Contact · Contact
701-323-5760OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122

Recruiting
Site Public Contact · Contact
701-234-6161OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219

Recruiting
Site Public Contact · Contact
513-584-7698cancer@uchealth.com
Bailey A. Nelson · Principal Investigator

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069

Recruiting
Site Public Contact · Contact
513-584-7698cancer@uchealth.com
Bailey A. Nelson · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Kelly L. Stratton · Principal Investigator

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Joseph M. Caster · Principal Investigator

Asplundh Cancer Pavilion

Willow Grove, Pennsylvania, 19090

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Joseph M. Caster · Principal Investigator

Sanford Cancer Center Oncology Clinic

Sioux Falls, South Dakota, 57104

Recruiting
Site Public Contact · Contact
605-312-3320OncologyClinicTrialsSF@sanfordhealth.org
Daniel Almquist · Principal Investigator

Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134

Recruiting
Site Public Contact · Contact
605-312-3320OncologyClinicalTrialsSF@SanfordHealth.org
Daniel Almquist · Principal Investigator

The West Clinic - Wolf River

Germantown, Tennessee, 38138

Recruiting
Site Public Contact · Contact
901-683-0055afletcher@westclinic.com
Daniel A. Vaena · Principal Investigator

Parkland Memorial Hospital

Dallas, Texas, 75235

Recruiting
Site Public Contact · Contact
214-590-5582canceranswerline@UTSouthwestern.edu
Suzanne M. Cole · Principal Investigator

UT Southwestern Simmons Cancer Center - RedBird

Dallas, Texas, 75237

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@utsouthwestern.edu
Suzanne M. Cole · Principal Investigator

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@UTSouthwestern.edu
Suzanne M. Cole · Principal Investigator

UT Southwestern/Simmons Cancer Center-Fort Worth

Fort Worth, Texas, 76104

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@UTSouthwestern.edu
Suzanne M. Cole · Principal Investigator

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030

Recruiting
Site Public Contact · Contact
713-798-1354burton@bcm.edu
Daniel A. Hamstra · Principal Investigator

UT Southwestern Clinical Center at Richardson/Plano

Richardson, Texas, 75080

Recruiting
Site Public Contact · Contact
972-669-7044Suzanne.cole@utsouthwestern.edu
Suzanne M. Cole · Principal Investigator

University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229

Recruiting
Site Public Contact · Contact
210-450-3800phoresearchoffice@uthscsa.edu
Chul S. Ha · Principal Investigator

Dartmouth Cancer Center - North

Saint Johnsbury, Vermont, 05819

Recruiting
Site Public Contact · Contact
800-639-6918cancer.research.nurse@hitchcock.org
James B. Yu · Principal Investigator

VCU Massey Cancer Center at Stony Point

Richmond, Virginia, 23235

Recruiting
Site Public Contact · Contact
ctoclinops@vcu.edu
Alfredo I. Urdaneta · Principal Investigator

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298

Recruiting
Site Public Contact · Contact
804-628-6430CTOclinops@vcu.edu
Alfredo I. Urdaneta · Principal Investigator

Swedish Medical Center-First Hill

Seattle, Washington, 98122

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Charles W. Drescher · Principal Investigator

West Virginia University Healthcare

Morgantown, West Virginia, 26506

Recruiting
Site Public Contact · Contact
304-293-7374cancertrialsinfo@hsc.wvu.edu
Muhammad Mohsin Fareed · Principal Investigator

Camden Clark Medical Center

Parkersburg, West Virginia, 26101

Recruiting
Site Public Contact · Contact
304-293-7374cancertrialsinfo@hsc.wvu.edu
Muhammad Mohsin Fareed · Principal Investigator

Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, 54301

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay, Wisconsin, 54303

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Saint Vincent Hospital Cancer Center at Oconto Falls

Oconto Falls, Wisconsin, 54154

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Saint Vincent Hospital Cancer Center at Sheboygan

Sheboygan, Wisconsin, 53081

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator

Saint Vincent Hospital Cancer Center at Sturgeon Bay

Sturgeon Bay, Wisconsin, 54235-1495

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Matthew L. Ryan · Principal Investigator